IGM Biosciences Inc
NASDAQ:IGMS
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.08
17.83
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one IGMS stock under the Base Case scenario is 3.75 USD. Compared to the current market price of 8.89 USD, IGM Biosciences Inc is Overvalued by 58%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
IGM Biosciences Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for IGMS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
IGM Biosciences Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
IGM Biosciences Inc
Balance Sheet Decomposition
IGM Biosciences Inc
Current Assets | 229.6m |
Cash & Short-Term Investments | 218.8m |
Other Current Assets | 10.8m |
Non-Current Assets | 74.9m |
PP&E | 73.7m |
Other Non-Current Assets | 1.1m |
Current Liabilities | 44m |
Accounts Payable | 3.5m |
Accrued Liabilities | 37.8m |
Other Current Liabilities | 2.7m |
Non-Current Liabilities | 181.6m |
Other Non-Current Liabilities | 181.6m |
Earnings Waterfall
IGM Biosciences Inc
Revenue
|
2.9m
USD
|
Operating Expenses
|
-223.6m
USD
|
Operating Income
|
-220.7m
USD
|
Other Expenses
|
886k
USD
|
Net Income
|
-219.8m
USD
|
Free Cash Flow Analysis
IGM Biosciences Inc
USD | |
Free Cash Flow | USD |
IGMS Profitability Score
Profitability Due Diligence
IGM Biosciences Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
IGM Biosciences Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
IGMS Solvency Score
Solvency Due Diligence
IGM Biosciences Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
IGM Biosciences Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IGMS Price Targets Summary
IGM Biosciences Inc
According to Wall Street analysts, the average 1-year price target for IGMS is 19.99 USD with a low forecast of 9.09 USD and a high forecast of 50.4 USD.
Dividends
Current shareholder yield for IGMS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
IGMS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 192 full-time employees. The company went IPO on 2019-09-18. The company has developed an IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Its lead product candidate, IGM-2323, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in an ongoing Phase I clinical trial for the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients. Its second product candidate, IGM-8444, is an IgM antibody targeting Death Receptor 5 (DR5) proteins, which is for the treatment of patients with solid and hematologic malignancies. The Company’s pipeline also includes IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
Contact
IPO
Employees
Officers
The intrinsic value of one IGMS stock under the Base Case scenario is 3.75 USD.
Compared to the current market price of 8.89 USD, IGM Biosciences Inc is Overvalued by 58%.